[Percutaneous administration of recombinant human bone morphogenetic protein-7 (rhBMP-7) after callus distraction. Two case reports].
Two cases of increased bone density after callus distraction are described following percutaneous administration of 3.5 mg recombinant bone morphogenetic protein-7 (rhBMP-7). Both patients underwent segmental resection and segmental transport for osteomyelitis of the long bones (femur and tibia) but no callus maturation occurred. After percutaneous administration of rhBMP-7 the callus density increased in both cases.
Högel
F
F
Abt. für Orthopädie und Unfallchirurgie, Berufsgenossenschaftliche Unfallklinik Murnau e.V., Prof.-Küntscher-Str. 8, 82418, Murnau, Deutschland. florian.hoegel@bgu-murnau.de
Militz
M
M
Bühren
V
V
Augat
P
P
Wagner
F
F
D000287:Administration, Topical; D000328:Adult; D055419:Bone Morphogenetic Protein 7 / Q000008:administration & dosage*; D002146:Bony Callus / Q000187:drug effects*; D017102:Fracture Healing / Q000187:drug effects*; D006801:Humans; D036341:Intercellular Signaling Peptides and Proteins / Q000008:administration & dosage; D008297:Male; D010000:Osteitis / Q000150:complications / Q000188:drug therapy* / Q000601:surgery*; D019857:Osteogenesis, Distraction; D016896:Treatment Outcome; D055815:Young Adult
C525819:BMP7 protein, human; D055419:Bone Morphogenetic Protein 7; D036341:Intercellular Signaling Peptides and Proteins